The Concept of CMR

References

1. Murray R, Mayes PA and Rodwell VW. Harper's Biochemistry. McGraw-Hill Companies. 2003.
2. Huang S and Czech MP. The GLUT4 glucose transporter. Cell Metab 2007; 5: 237-52.
3. Thirone AC, Huang C and Klip A. Tissue-specific roles of IRS proteins in insulin signaling and glucose transport. Trends Endocrinol Metab 2006; 17: 72-8.
4. Prentki M. New insights into pancreatic beta-cell metabolic signaling in insulin secretion. Eur J Endocrinol 1996; 134: 272-86.
5. Chang L, Chiang SH and Saltiel AR. Insulin signaling and the regulation of glucose transport. Mol Med 2004; 10: 65-71.
6. Arner P. The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol Metab 2003; 14: 137-45.
7. Quinn PG and Yeagley D. Insulin regulation of PEPCK gene expression: a model for rapid and reversible modulation. Curr Drug Targets Immune Endocr Metabol Disord 2005; 5: 423-37.
8. Després JP, Moorjani S, Lupien PJ, et al. Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis 1990; 10: 497-511.
9. Pouliot MC, Després JP, Nadeau A, et al. Visceral obesity in men. Associations with glucose tolerance, plasma insulin, and lipoprotein levels. Diabetes 1992; 41: 826-34.
10. Ross R, Aru J, Freeman J, et al. Abdominal adiposity and insulin resistance in obese men. Am J Physiol Endocrinol Metab 2002; 282: E657-63.
11. Ross R, Freeman J, Hudson R, et al. Abdominal obesity, muscle composition, and insulin resistance in premenopausal women. J Clin Endocrinol Metab 2002; 87: 5044-51.
12. Gregor MG and Hotamisligil GS. Adipocyte stress: The endoplasmic reticulum and metabolic disease. J Lipid Res 2007.
13. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444: 860-7.
14. Lumeng CN, Bodzin JL and Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 2007; 117: 175-84.
15. Kanda H, Tateya S, Tamori Y, et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 2006; 116: 1494-505.
16. Weisberg SP, Hunter D, Huber R, et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 2006; 116: 115-24.
17. Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796-808.
18. Yu R, Kim CS, Kwon BS, et al. Mesenteric adipose tissue-derived monocyte chemoattractant protein-1 plays a crucial role in adipose tissue macrophage migration and activation in obese mice. Obesity (Silver Spring) 2006; 14: 1353-62.
19. Shoelson SE, Herrero L and Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology 2007; 132: 2169-80.
20. Shoelson SE, Lee J and Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116: 1793-801.
21. Skurk T, Alberti-Huber C, Herder C, et al. Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab 2007; 92: 1023-33.
22. Koutsari C and Jensen MD. Thematic review series: patient-oriented research. Free fatty acid metabolism in human obesity. J Lipid Res 2006; 47: 1643-50.
23. Savage DB, Petersen KF and Shulman GI. Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol Rev 2007; 87: 507-20.
24. Prentki M and Nolan CJ. Islet beta cell failure in type 2 diabetes. J Clin Invest 2006; 116: 1802-12.
25. Kahn SE, Hull RL and Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006; 444: 840-6.
26. American Diabetes Association. Diagnosis and classification of Diabetes Mellitus. Diabetes Care 2007; 30 (Suppl. 1): S42-S7.
27. Rossetti L, Giaccari A and DeFronzo RA. Glucose toxicity. Diabetes Care 1990; 13: 610-30.
28. Stumvoll M, Goldstein BJ and van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005; 365: 1333-46.
29. Yan SF, Yan SD, Herold K, et al. Receptor for advanced glycation end products and the cardiovascular complications of diabetes and beyond: lessons from AGEing. Endocrinol Metab Clin North Am 2006; 35: 511-24, viii.
30. Bansilal S, Farkouh ME and Fuster V. Role of insulin resistance and hyperglycemia in the development of atherosclerosis. Am J Cardiol 2007; 99: 6B-14B.
31. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-12.
32. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 854-65.
33. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-53.
34. Nitenberg A, Cosson E and Pham I. Postprandial endothelial dysfunction: role of glucose, lipids and insulin. Diabetes Metab 2006; 32 Spec No2: 2S28-33.